



The office for the second of t

d d v

APPLICATION NO	HEING DATE	EIRSEN AMED INVENTOR	ATTORNEY DOCKLENO	CONTRACTON NO
09 651,846	08/31/2000	Limothy HIa	UCT-00i2	4421
23413 75	690 - 64 01 2003			
CANTOR COLBURN, LLP			L NAMES IN	
55 GRIFFIN ROAD SOUTH			SCHMIDT, MAKEM	
BLOOMFIELD, CT 06002				
			8.00 (10.00)	1120 11 116 11
			to s *	

Please find below and or attached an Office communication concerning this application of proceeding

UNITED STAT EPARTMENT OF COMMERCE Patent and Trademark Office
ADDRESS:
ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231

CONTROL NO.

FILING DATE

PATENT UNDER REEXAMINATION

ATTY, DOCKET NO.

09/651,846

**EXAMINER** 

ART UNIT

PAPER NUMBER

25

**DATE MAILED:** 

Please find below and/or attached an Office communication concerning the above identified reexamination proceeding.

Commissioner of Patents and Trademarks

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Applicant is given ONE MONTH from the mailing date of this communication within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to *Mary M. Schmidt*, whose telephone number is (703) 308-4471.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, *John LeGuyader*, may be reached at (703) 308-0447.

Any inquiry of a general nature or relating to the status of this application should be directed to Katrina Turner, whose telephone number is (703) 305-3413.

M. M. Schmidt

March 25, 2003

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the

following reason(s):

	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
X	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7. Other:
Ар	plicant Must Provide:
X	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
久	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
Fo	r questions regarding compliance to these requirements, please contact:
	Rules Interpretation, call (703) 308-4216
	r CRF Submission Help, call (703) 308-4212
Pa	tentIn Software Program Support (SIRA)

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

Derangsh Patentin Sattwark

E 30M-190